Movement Alert｜GlaxoSmithKline PLC Rises 3.32% in Pre-Market Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial

Market Focus09-14 18:03

On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.

The stock gained momentum after the company announced that its lung cancer drug zidesamtinib (marketed as Jideytro) achieved a 94% overall response rate in previously untreated patients with advanced ROS1-positive non-small cell lung cancer. Notably, all trial participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. The safety profile was favorable, with treatment-related adverse events leading to dose reductions in only 11% of patients and discontinuations in just 1%.

Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer. The company plans to submit an application to the FDA this year to expand the drug's label to include first-line treatment. The strong efficacy data bolsters the drug's blockbuster sales potential and reinforces GSK's growing oncology pipeline, which has been a strategic priority alongside its cost-savings target of 1.9 billion pounds annually by 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183831307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183831307","market":"us","top_or_hot":-1,"title":"Movement Alert｜GlaxoSmithKline PLC Rises 3.32% in Pre-Market Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial","media":"Market Focus","content":"<p><p>On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.</p><p>The stock gained momentum after the company announced that its lung cancer drug zidesamtinib (marketed as Jideytro) achieved a 94% overall response rate in previously untreated patients with advanced ROS1-positive non-small cell lung cancer. Notably, all trial participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. The safety profile was favorable, with treatment-related adverse events leading to dose reductions in only 11% of patients and discontinuations in just 1%.</p><p>Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer. The company plans to submit an application to the FDA this year to expand the drug's label to include first-line treatment. The strong efficacy data bolsters the drug's blockbuster sales potential and reinforces GSK's growing oncology pipeline, which has been a strategic priority alongside its cost-savings target of 1.9 billion pounds annually by 2029.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GlaxoSmithKline PLC Rises 3.32% in Pre-Market Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GlaxoSmithKline PLC Rises 3.32% in Pre-Market Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.</p><p>The stock gained momentum after the company announced that its lung cancer drug zidesamtinib (marketed as Jideytro) achieved a 94% overall response rate in previously untreated patients with advanced ROS1-positive non-small cell lung cancer. Notably, all trial participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. The safety profile was favorable, with treatment-related adverse events leading to dose reductions in only 11% of patients and discontinuations in just 1%.</p><p>Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer. The company plans to submit an application to the FDA this year to expand the drug's label to include first-line treatment. The strong efficacy data bolsters the drug's blockbuster sales potential and reinforces GSK's growing oncology pipeline, which has been a strategic priority alongside its cost-savings target of 1.9 billion pounds annually by 2029.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1183831307","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183831307","pubTimestamp":1789380184,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.The stock gained momentum after the company announced that its lung cancer...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"动向提醒|葛兰素史克盘前交易涨3.32%，肺癌药物Jideytro一线试验应答率达94%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.The stock gained momentum after the company announced that its lung cancer drug zidesamtinib (marketed as Jideytro) achieved a 94% overall response rate in previously untreated patients with advanced ROS1-positive non-small cell lung cancer. Notably, all trial participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. The safety profile was favorable, with treatment-related adverse events leading to dose reductions in only 11% of patients and discontinuations in just 1%.Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer. The company plans to submit an application to the FDA this year to expand the drug's label to include first-line treatment. The strong efficacy data bolsters the drug's blockbuster sales potential and reinforces GSK's growing oncology pipeline, which has been a strategic priority alongside its cost-savings target of 1.9 billion pounds annually by 2029.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183831307","isCrawlerRequest":true}